Form 4: Voyager Therapeutics Director Granted Stock Options

Voyager Therapeutics reports that Director Steven Hyman was granted 30,000 stock options under the company's 2025 Stock Incentive Plan.

Summary

• Steven Hyman, a Director at Voyager Therapeutics, Inc., was granted 30,000 stock options on June 9, 2026.
• These options have an exercise price of $3.43 and an expiration date of June 9, 2036.
• The options were issued under the company's 2025 Stock Incentive Plan as part of the director compensation policy.
• Vesting of the options commences on the grant date and will be completed upon the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director compensation event rather than a significant financial or strategic development.

Positives

• Director compensation through stock options aligns management incentives with shareholder value.
• The grant of options indicates continued confidence in the company's future prospects by its directors.

Risks

• The value of the stock options is subject to market fluctuations and the company's future performance.
• Vesting is contingent on continued service, meaning the director could forfeit unvested options if service ceases before vesting milestones are met.

Future Outlook

The future outlook is implicitly positive as stock options are granted, suggesting management expects the stock price to increase.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to retain talent and align executive interests with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The grant of options may lead to future dilution if exercised, but also aligns director incentives with increasing shareholder value.
• Employees: This filing does not directly impact employees but reflects standard compensation practices within the company.
• Management: Directors are incentivized to perform well to increase the value of their options.

Next Steps

• Steven Hyman will continue his service as a director to meet vesting requirements.
• The stock options will vest according to the schedule outlined in the filing.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Form 4, Stock Options, Director Compensation, Insider Trading, SEC Filing, Equity Incentive Plan